How Much Does a Peptide Therapy Clinic Owner Make? $500k EBITDA
Key Takeaways
Patient volume must cover fixed overhead and payroll.
Pricing per visit drives revenue before cost cuts.
Margin hinges on peptide, lab, and supply costs.
Retention and efficient acquisition protect cash flow.
Owner income$500k-$7.7M EBITDAGross margin87%Revenue for target pay$85kBusiness difficultyHard
Want to estimate your clinic take-home?
Owner income calculator
Estimate owner take-home and the target-pay gap from monthly revenue, gross margin, payroll, overhead, reserves, and target pay.
!
Planning note: Research-based planning estimate only. It is not guaranteed salary, tax advice, or owner distribution advice. Actual owner income depends on revenue, margin, payroll, reserves, and debt.
Want to pressure-test the Peptide Therapy Clinic model?
This dashboard should show revenue, EBITDA, owner income, breakeven, payback, and cash need; open the Peptide Therapy Clinic Financial Model Template to test provider count, monthly treatments, capacity, price, COGS, payroll, overhead, and capex. Use Year 1, Year 3, and Year 5 scenarios.
Key model checks
Owner income output
Capacity-driven revenue build
Scenario charts and tables
How much can a peptide therapy clinic owner make?
A Peptide Therapy Clinic owner can make what remains after expenses and reserves, not revenue alone; the researched model shows $500k Year 1 EBITDA on $1.469M revenue, rising to $7.668M Year 5 EBITDA on $9.272M revenue. EBITDA means profit before interest, taxes, depreciation, and amortization, so safe owner draw should leave cash for taxes, debt service, inventory, compliance, staffing, and marketing; use How To Write A Business Plan For Peptide Therapy Clinic? to map that cash plan.
Income drivers
$500k Year 1 EBITDA
$1.469M Year 1 revenue
$7.668M Year 5 EBITDA
$9.272M Year 5 revenue
Draw limits
Reserve for taxes
Cover debt service
Fund inventory and compliance
Watch patient volume, provider use, pricing
How does the owner’s role change peptide therapy clinic income?
Owner-operated income can look stronger in a Peptide Therapy Clinic because the owner may replace paid management or clinical labor, but that also means they are buying a job with their time. A delegated provider model adds capacity, yet it also raises payroll, oversight, scheduling, and compliance work. Here’s the quick math: staffing can scale from 1 Medical Doctor, 1 Nurse Practitioner, and 2 Registered Nurses in Year 1 to 3 Medical Doctors, 5 Nurse Practitioners, and 6 Registered Nurses in Year 5, so passive ownership is not simple.
Owner-led income
Higher take-home if labor is self-run.
No paid manager lowers fixed cost.
Owner time becomes the bottleneck.
One-liner: more control, less freedom.
Delegated model
More providers increase treatment capacity.
Payroll grows with each role added.
Compliance work still needs active oversight.
One-liner: scale is real, so is control.
Are peptide therapy clinics profitable after operating costs?
If you’re asking whether a Peptide Therapy Clinic can be profitable after operating costs, the answer is yes under the researched assumptions. The clinic is profitable from Month 1, with $500k Year 1 EBITDA and a 340% EBITDA margin; see How To Launch Peptide Therapy Clinic Business? for the setup path. Direct peptide and lab costs are 130% of revenue in Year 1 and fall to 112% by Year 5, so the margin depends on volume and cost control.
Why it works
$500k Year 1 EBITDA
340% EBITDA margin
Profitable from Month 1
Costs improve to 112% by Year 5
What can break it
$125k monthly lease
$32k malpractice and liability insurance
$11k EMR and HIPAA software
$18k utilities and maintenance
Peptide Therapy Clinic Financial Model
5-Year Financial Projections
100% Editable
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Accounting Or Financial Knowledge
Want to see what drives owner income?
1
Patient Volume
122K-773K/mo
More visits lift revenue from about $122K a month in Year 1 to about $773K a month in Year 5, and that scale drives most owner cash.
2
Treatment Pricing
125-950
Prices run from $125 to $950, so even small raises spread across the whole schedule and add straight to take-home.
3
Gross Margin
87%
Peptide sourcing and lab fees take 13% of revenue, so about 87% stays to pay overhead and profit.
4
Provider Model
6-19 FTE
The care team scales from 6 to 19 FTE, so more treatments can be sold without one clinician capping revenue.
5
Retention
660/mo
Keeping follow-up patients on schedule protects the 660 monthly treatment slots already built into the plan.
6
Acquisition Efficiency
6.0-4.0
Digital marketing cost falls from 6.0 to 4.0, so less paid growth spend drops into profit after Month 1 breakeven.
Peptide Therapy Clinic Core Six Income Drivers
Patient Demand And Active Patient Count
Active Patient Count
Active patient count is the real revenue engine here: consults only matter if they turn into starts, then follow-ups, and then enough repeat visits to keep providers busy. The model assumes 408 treatments per month in Year 1 across provider types, so owner income rises only when those slots are filled without adding idle payroll or excess staff.
Here’s the quick math: more active patients spread fixed overhead and payroll across more visits, which lifts cash flow and profit. If demand is thin, adding providers too early pushes cost up before revenue catches up. One clean rule: volume before hiring.
Track Starts, Not Just Leads
Measure consult-to-start conversion, active patients per provider, and follow-up fill rate each month. Those three inputs tell you if the schedule can support more revenue or if you’re just buying empty capacity. If follow-ups do not stay full, owner pay falls even when lead flow looks healthy.
Use a simple control check: planned treatments versus actual treatments versus provider capacity. When starts lag, tighten scheduling, reactivation, and retention before hiring. If demand keeps pace with the modeled 408 monthly treatments, overhead absorption improves and take-home income has room to grow.
Consults that become starts
Active patients per provider
Follow-up fill rate each month
Unused capacity before hiring
1
Pricing And Revenue Per Patient
Pricing Per Patient
Pricing sets revenue per patient before any cost cut. Year 1 service prices are $850 for Medical Doctor visits, $450 for Nurse Practitioner visits, $250 for Registered Nurse visits, $175 for Health Coach visits, and $125 for Phlebotomist visits. If the visit mix stays the same, price alone can lift owner income without adding more patients.
By Year 5, those prices rise to $950, $510, $290, $195, and $145, which is about 11% to 16% higher by role. Packages, memberships, consult fees, and follow-up pricing can add more revenue, but only if patient demand and provider capacity support the extra touches.
Track Revenue per Active Patient
Measure revenue per active patient, not just visit count. Here’s the quick math: a higher-price mix raises top-line revenue first, then improves cash flow and owner draw if schedules stay full. A schedule heavy on Medical Doctor visits will pay more than one built around RN or Health Coach visits.
Track three things: visit mix, follow-up rate, and membership attach rate. Test package pricing only when open slots remain. If consult fees or follow-up prices rise but starts drop, total income can fall even with a better ticket.
Price by service level.
Watch capacity by provider.
Test follow-up conversion.
Protect revenue per patient.
2
Gross Margin After Peptide And Lab Costs
Gross Margin After Lab And Peptide Costs
When peptide sourcing and lab fees stay under control, more of each treatment dollar turns into cash that can cover payroll, marketing, rent, and owner pay. The model shows peptide sourcing at 85% of revenue and diagnostic lab fees at 45% in Year 1, then 75% and 37% by Year 5. The stated gross margin after those direct costs is 870% in Year 1 and 888% in Year 5, so the owner’s income depends on keeping clinical quality while tightening COGS.
What this includes is simple: peptide therapy supply cost, lab testing, and related direct materials. The key inputs are treatment revenue, peptide cost as a percent of revenue, lab fee as a percent of revenue, and any added supply cost, which is listed at 25% in Year 1. If sourcing slips or documentation is weak, margin can look better on paper than it is in cash.
Track COGS And Lab Cost Per Start
Track peptide cost per treatment, lab cost per patient, and gross margin by protocol. Here’s the quick math: if revenue rises but direct costs rise faster, the owner gets less cash for draw and overhead. Tie every protocol to a standard cost sheet so you can see where each test, vial, and supply line lands before it hits the P&L.
Improve this driver by reviewing vendor pricing, test ordering rules, and refill timing without cutting compliance. Use the same documentation standard on every chart, because weak sourcing or shortcuts can raise legal and cash risk at the same time. One clean rule helps: if a cost does not change care quality, it should be tested against margin before it becomes standard.
3
Provider Staffing And Medical Oversight
Provider Staffing and Medical Oversight
When staffing gets ahead of demand, owner pay gets squeezed fast. Year 1 fixed payroll is $285k for the Medical Director plus $95k Clinic Manager, $55k Patient Coordinator, $85k Marketing Manager, and $45k Front Desk Receptionist, or about $47.1k per month before any owner draw.
The clinic starts with 1 Medical Doctor and 1 Nurse Practitioner and scales to 3 Medical Doctors and 5 Nurse Practitioners by Year 5. That helps capacity, but only if supervision, scheduling, and compliance stay tight; otherwise payroll rises faster than revenue and cash flow gets thin.
Track provider load, not headcount
Measure visits per clinician, medical director time, and schedule fill rate, then tie hiring to booked demand. Here’s the quick math: the fixed team costs $565k a year, so every added provider needs enough booked, billable work to cover their share of overhead and still leave room for owner pay.
Track visits per provider weekly
Watch no-show and reschedule rates
Set supervision and chart review rules
Hire only against booked demand
Use one schedule, not ad hoc coverage
4
Retention And Recurring Follow-Up Revenue
Retention and Follow-Up Revenue
In a peptide clinic, retention means patients keep coming back for refills, follow-ups, and lab reviews instead of stopping after one cycle. That keeps the schedule full with fewer new consults, so revenue is steadier and more of the cash can reach the owner. In the model, revenue grows from $1,469M in Year 1 to $9,272M in Year 5 only when follow-up volume stays productive.
Track Repeats Before You Add Staff
Track repeat-visit rate, booked-next-visit rate, membership renewals, and the average days between visits. If the first-treatment cohort does not return, new leads have to replace them, which raises marketing pressure and makes profit less predictable. The fastest fix is simple: schedule the next refill or lab review before the patient leaves, so the next revenue date is already on the calendar.
Measure repeats by patient cohort.
Watch refill and lab gaps.
Track renewals and cancellations.
Fill open slots with existing patients first.
5
Marketing Efficiency And Acquisition Cost
Marketing Efficiency
For a peptide therapy clinic, marketing efficiency is the gap between spending on leads and getting paid starts. In the model, Year 1 digital marketing and acquisition = 60% of revenue, then falls to 40% by Year 5. That only helps owner income if consults turn into treatment plans fast enough to cover contribution margin and fixed payroll. If they do not, EBITDA gets squeezed.
Here’s the quick math: watch cost per qualified consult, consult-to-start conversion, revenue per active patient, and payback period. One bad step in the funnel can turn growth into cash burn. The owner pays for wasted leads twice: once in marketing spend and again in idle clinical capacity.
Tighten Acquisition Payback
Track each source from lead to start, then stop buying traffic that does not produce enough margin. Keep spend tied to contribution, not lead volume. That is the cleanest way to protect take-home income.
Measure qualified consult cost
Track start rate by source
Compare payback by campaign
Watch revenue per active patient
If leads convert slowly or into low-margin plans, cut spend fast. If acquisition is efficient, faster payback frees cash for staffing, retention, and owner pay.
6
Peptide Therapy Clinic Business Plan
30+ Business Plan Pages
Investor/Bank Ready
Pre-Written Business Plan
Customizable in Minutes
Immediate Access
Compare launch, growth, and mature owner-income scenarios
Owner income scenarios
Owner income changes quickly here because staffing, compliance, marketing, and cash needs rise with volume. The three cases show how Year 1, Year 3, and Year 5 model results affect cash left for the owner.
Compare low, base, and high owner income cases by model year.
Scenario
Low CaseCash tight
Base CaseScale path
High CaseUpside
Launch model
This is the launch-year owner-income case, with modest cash left after taxes, debt, reserves, and reinvestment.
This is the growth-year owner-income case, with stronger cash left as volume and staffing scale.
This is the mature-year owner-income case, with the strongest modeled cash left if the clinic keeps scaling.
Typical setup
Year 1 models $1.469M revenue and $500k EBITDA, about 34.0% EBITDA margin, with 408 monthly treatments and Month 1 breakeven.
Year 3 models $4.621M revenue and $3.724M EBITDA, about 80.6% EBITDA margin, with a larger clinical team and steadier utilization.
Year 5 models $9.272M revenue and $7.668M EBITDA, about 82.7% EBITDA margin, with a full team, fuller capacity, and 13-month payback.
Cost drivers
Lower volume
fixed lease and insurance
peptide and lab costs
marketing spend
early staffing mix
Higher volume
added clinical staff
stronger pricing
ongoing compliance
marketing efficiency
Top volume
larger care team
higher prices
lower unit costs
reinvestment pace
Owner income rangeBefore owner reserves
Launch-year owner drawTight cash
Growth-year owner drawGrowth case
Mature-year owner drawUpside case
Best fit
Use this to stress-test take-home pay if growth is slower and the clinic stays lean.
Use this as the planning case for a clinic that reaches Year 3 scale without a major cash squeeze.
Use this to test upside if utilization, pricing, and staffing all land near plan.
!
Planning note: Scenario ranges are researched planning assumptions, not guaranteed earnings, salary promises, tax advice, or distributions.
In the researched model, the clinic produces $500k of Year 1 EBITDA on $1469M of revenue That equals about a 340% EBITDA margin before taxes, debt service, reserves, and owner distributions By Year 5, EBITDA reaches $7668M on $9272M of revenue, but that assumes much higher staffing, capacity, and demand
The model shows breakeven in Month 1 and a 13-month payback period That result depends on strong early treatment volume, with about $122k in average monthly Year 1 revenue The business also needs $746k of minimum cash by Month 6, so breakeven does not mean the owner can drain cash early
Yes, the researched model shows a $746k minimum cash need, with the lowest cash point in Month 6 Startup capital expenses include $185k for buildout, $75k for diagnostic equipment, $35k for initial inventory, and $25k for IT infrastructure Keep reserves separate from owner pay because medical clinics carry timing, compliance, and inventory risk
Patient volume, provider utilization, treatment pricing, direct COGS, payroll, and marketing efficiency affect owner pay most Year 1 direct peptide and lab costs total 130% of revenue, while digital marketing adds 60% Fixed overhead is $20k per month before listed management payroll, so underused capacity can hurt take-home quickly
The best structure separates salary, profit distributions, taxes, debt service, and reserves The model reports EBITDA, not guaranteed owner salary A practical approach is to set a base owner pay target, maintain operating reserves, then distribute only excess cash after payroll, $20k monthly fixed overhead, clinical costs, and reinvestment needs are covered
About the author
Stephen Knight
Business Idea Researcher
Stephen Knight is a business idea researcher at Financial Models Lab who focuses on revenue and profit basics for founders building a simple business plan. He breaks down business model overviews in plain English, helping non-finance readers understand what it really takes to open a physical location and turn an idea into a workable plan.
Choosing a selection results in a full page refresh.
